Navigation Links
FightSMA Launches Gene Therapy Fundraising Campaign: “Realizing the Dream”
Date:7/8/2010

Fight SMA partners with the Gwendolyn Strong Foundation on a fundraising campaign for spinal muscular atrophy gene therapy.

(PRWEB) July 8, 2010 -- Richmond-based FightSMA announced today a new fundraising campaign for SMA gene therapy, “Realizing the Dream.” FightSMA is collaborating with the Santa Barbara –based Gwendolyn Strong Foundation, to form a bi-coastal partnership with a common goal: to bring SMA gene therapy to clinical trial.    “Ten years ago, it would have been unheard of to say scientists were approaching a treatment or cure for spinal muscular atrophy (SMA),” said FightSMA President Martha Slay. “Today, the dream is being realized in some of the most prestigious labs across the country. Never before has there been such promise for SMA gene therapy.” Beginning now and for the next three years, families and groups in the SMA community will raise funds to build a safe foundation, deliver genes to an SMA model, and produce adequate vector (gene delivery) supply. These efforts will support Dr. Brian Kaspar of Nationwide Children’s Hospital and The Ohio State University and other collaborating scientists. FightSMA, working with the Gwendolyn Strong Foundation, a funding source for critical SMA science and awareness initiatives, invites the SMA community to make a decade-old dream come true. “Our SMA gene therapy program at Nationwide Children’s Hospital and the Ohio State University continues to show great promise for treating SMA patients,” said Dr. Kaspar. FightSMA’s objective for the balance of 2010 is to complete funding for Phase One, and for Year-One of Phase-Two of the research program. “The first objective is to build a solid foundation of safety and to eliminate toxicity,” said Dr. Chris Lorson, FightSMA Science Director.” Additionally, FightSMA plans to raise another $250,000 to fund the first year of Phase Two (Delivery & Efficacy). The “Realizing the Dream” program will be accomplished through a series of campaigns. Completing these two Phases will bring SMA gene therapy significantly closer to clinical trial.    FightSMA has been instrumental in helping to develop a gene therapy strategy to cure spinal muscular atrophy (SMA), including oligonucleotides and gene replacement vectors. The strides that SMA researchers have made in the gene therapy arena have provided insights into a range of genetic disorders, including other neurodegenerative disease (ALS/Lou Gehrig's disease, myotonic dystrophy, Huntington disease) and other diseases such as Duchenne muscular dystrophy. For more information on the FightSMA – Gwendolyn Strong Foundation partnership and “Realizing the Dream” campaign, visit FightSMA announced today a new fundraising campaign for SMA gene therapy, “Realizing the Dream.”  FightSMA is collaborating with the Santa Barbara –based Gwendolyn Strong Foundation, to form a bi-coastal partnership with a common goal: to bring SMA gene therapy to clinical trial.
 
 “Ten years ago, it would have been unheard of to say scientists were approaching a treatment or cure for spinal muscular atrophy (SMA),” said FightSMA President Martha Slay.  “Today, the dream is being realized in some of the most prestigious labs across the country.  Never before has there been such promise for SMA gene therapy.”
 
Beginning now and for the next three years, families and groups in the SMA community will raise funds to build a safe foundation, deliver genes to an SMA model, and produce adequate vector (gene delivery) supply.   These efforts will support Dr. Brian Kaspar of Nationwide Children’s Hospital and The Ohio State University and other collaborating scientists. 

FightSMA, working with the Gwendolyn Strong Foundation, a funding source for critical SMA science and awareness initiatives, invites the SMA community to make a decade-old dream come true. “Our SMA gene therapy program at Nationwide Children’s Hospital and the Ohio State University continues to show great promise for treating SMA patients,” said Dr. Kaspar.
 
FightSMA’s objective for the balance of 2010 is to complete funding for Phase One, and for Year-One of Phase-Two of the research program. 

“The first objective is to build a solid foundation of safety and to eliminate toxicity,” said Dr. Chris Lorson, FightSMA Science Director.”

Additionally, FightSMA plans to raise another $250,000 to fund the first year of Phase Two (Delivery & Efficacy).  The “Realizing the Dream” program will be accomplished through a series of campaigns.  Completing these two Phases will bring SMA gene therapy significantly closer to clinical trial. 
 
FightSMA has been instrumental in helping to develop a gene therapy strategy to cure spinal muscular atrophy (SMA), including oligonucleotides and gene replacement vectors. The strides that SMA researchers have made in the gene therapy arena have provided insights into a range of genetic disorders, including other neurodegenerative disease (ALS/Lou Gehrig's disease, myotonic dystrophy, Huntington disease) and other diseases such as Duchenne muscular dystrophy.

For more information on the FightSMA – Gwendolyn Strong Foundation partnership and “Realizing the Dream” campaign, visit www.fighsma.org or call 804-515-0080.

FightSMA was created to strategically accelerate the search for a treatment and cure for spinal muscular atrophy (SMA), the number-one inherited cause of infant death. The organization pursues this objective by raising awareness and funding for SMA research For more information, please visit http://fightsma.org.
 
###

Read the full story at http://www.prweb.com/releases/2010/07/prweb4232554.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Hooper Holmes Heritage Labs Division Launches New Home Diabetes Test
2. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
3. StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress
4. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
5. ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
6. ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration
7. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
8. Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC
9. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
10. SearchMedica Launches Practice Management Search Engine for Medical Professionals
11. Familybuilder Launches the Familybuilder Global Network at DEMOfall 08
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FightSMA Launches Gene Therapy Fundraising Campaign: “Realizing the Dream” 
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy ... President of Clinical Operations. She brings years of expertise in establishing and leading ... professional foundation as a licensed occupational therapist, through a variety of leadership roles ...
(Date:5/23/2017)... Boston, Massachusetts (PRWEB) , ... May 23, 2017 , ... ... is making a splash at this year’s Bio-IT World Conference and Expo ... Anzo Smart Data Lake® 4.0 solution. The Anzo Smart Data Lake is also ...
(Date:5/22/2017)... ... , ... Stratevi, a boutique firm that partners with healthcare companies to creatively ... office in downtown Boston at 745 Atlantic Ave. , “We are seeing that ... on the value they provide, not just to patients, but also payers. Having a ...
(Date:5/22/2017)... PA (PRWEB) , ... May 22, 2017 , ... ... announced today that it is exhibiting in booth B2 at the Association for ... Pittsburgh, May 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit ...
Breaking Biology Technology:
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
Breaking Biology News(10 mins):